REFERENCE
Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K.Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Journal of Managed Care Pharmacy 13: 245-261, No. 3, Apr 2007
Rights and permissions
About this article
Cite this article
Glatiramer acetate best bet in RRMS?. Pharmacoecon. Outcomes News 531, 5 (2007). https://doi.org/10.2165/00151234-200705310-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705310-00008